JPM | US Special Situations Daily: June 22, 2026

Research evidence excerpt

JPM | US Special Situations Daily: June 22, 2026

Neetu Jhamb - Specialist Sales - US Special Situations AC (1-212) 272-5971 North America Specialist Sales 22 June 2026

neetu.jhamb@jpmorgan.com JPM | US Special Situations Daily: J P M O R G A N

J.P. Morgan Securities LLC CRH nears deal to acquire Arcosa,

AbbVie to Acquire Apogee

Therapeutics, CWAN June 24th last

trading day, GTLS/BKR submit EC

remedies, maintain July closing

• Reinforces CRH’s position as the #1 infrastructure player in North America.

• Advances CRH’s strategy to build an aggregates-led, connected portfolio.

• Increases exposure to high-growth U.S. MSAs and critical infrastructure markets.

• Highly complementary businesses, expanding CRH’s offering and addressable market.

• Accretive to CRH’s earnings, margin, and cash flow within 12 months post-completion.

• Aligned with CRH’s disciplined capital deployment and 2030 financial targets.

• Maintains strong investment grade credit rating (pro forma FY 2026E Net Debt / Adjusted EBITDA of 2.4x).

• MERGER AGREEMENT SUMMARY:

• Filing dates: Prelim proxy within 25 business days (July 24, 2026). HSR within 10 business days (July 3, 2026). Any

other required filings shall be made promptly.

• Limitation on divestitures provision: provided, however, that nothing in this Agreement shall require Parent to agree or

commit to any Regulatory Remedial Action (x) that is not conditioned on the consummation of the Merger or (y) if

such action would require the divestiture or holding separate (or any other Regulatory Remedial Action) of or with

respect to assets, businesses, or product lines of Parent, the Company or their respective Subsidiaries, or any

combination thereof representing, in the aggregate, an amount in excess of the amount set forth, with respect to each